About Ryeqo

RYEQO®: PBS-LISTED FOR ENDOMETRIOSIS1

Ryeqo is the first oral GnRH antagonist combined with add-back therapy PBS-listed for the symptomatic treatment of endometriosis in Australia1

Designed to delicately balance efficacy & safety:2,3

Ryeqo is indicated in adult women of reproductive age for:2

Symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis
Treatment of moderate to severe symptoms of uterine fibroids

Abbreviations: ABT, add-back therapy; BMD, bone mineral density; E2, estradiol; GnRH, gonadotropin-releasing hormone.

‍

References:

  1. Schedule of Pharmaceutical Benefits, May 2025
  2. Ryeqo Approved Product Information. August 2025.
  3. Giudice LC et al. Lancet. 2022;399:2267–2279. 
Cookie Settings

We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy.

PreferencesRejectAccept
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Preferences